{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:26:24Z","timestamp":1789539984873,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02828-1","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:34:41Z","timestamp":1759311281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective study on HIV virological recovery patterns and factors associated with HIV viral treatment using highly active antiretroviral therapy (HAART) in public health facilities in tigray, Northern Ethiopia"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2516-4680","authenticated-orcid":false,"given":"Gebrecherkos Teame","family":"Gebrehiwot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Tilahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-4818","authenticated-orcid":false,"given":"Gebreselema","family":"Gebreyohannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataklti","family":"Gessese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haileselassie","family":"Bisrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagnew","family":"Weldegiorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tekele","family":"Amare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisseha","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girmay","family":"Alemseged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2680-2102","authenticated-orcid":false,"given":"Gebreselassie","family":"Alemseged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayelom","family":"Kahsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"13","key":"2828_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853\u201360.","journal-title":"N Engl J Med"},{"key":"2828_CR2","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016."},{"issue":"9","key":"2828_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WD Venter","year":"2019","unstructured":"Venter WD, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"2828_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral Society\u2013USA panel. JAMA. 2023;329(1):63\u201384.","journal-title":"JAMA"},{"key":"2828_CR5","unstructured":"UNAIDS GH. AIDS statistics\u2014Fact sheet [Internet]. 2022 [cited 2023 May 30]."},{"key":"2828_CR6","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013."},{"key":"2828_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-019-4659-z","volume":"19","author":"H Ghiasvand","year":"2019","unstructured":"Ghiasvand H, et al. Clinical determinants associated with quality of life for people who live with HIV\/AIDS: a meta-analysis. BMC Health Serv Res. 2019;19:1\u201311.","journal-title":"BMC Health Serv Res"},{"issue":"02","key":"2828_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4236\/wja.2014.42031","volume":"4","author":"RH Dennin","year":"2014","unstructured":"Dennin RH, Lafrenz M, Gesk G. HIV and other sexual transmitted Infections\u2014Challenges for Liberal prevention strategies. World J AIDS. 2014;4(02):258\u201379.","journal-title":"World J AIDS"},{"key":"2828_CR9","doi-asserted-by":"crossref","unstructured":"Kiros T et al. Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at Delgi primary hospital, Northwest ethiopia, 2020\/2021: A cross-sectional study. Heliyon, 2022. 8(8).","DOI":"10.1016\/j.heliyon.2022.e10169"},{"issue":"3","key":"2828_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s44197-023-00097-1","volume":"13","author":"SA Awaidy","year":"2023","unstructured":"Awaidy SA, Ghazy RM, Mahomed O. Progress of the Gulf Cooperation Council (gcc) countries towards achieving the 95-95-95 UNAIDS targets: a review. J Epidemiol Global Health. 2023;13(3):397\u2013406.","journal-title":"J Epidemiol Global Health"},{"key":"2828_CR11","unstructured":"Organization WH. Global action plan on HIV drug resistance 2017\u20132021. 2017."},{"key":"2828_CR12","unstructured":"Global A. update 2016 [http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-AIDS-update-2016_en.pdf]. 2017, Accessed."},{"key":"2828_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-28","volume":"14","author":"A Mulu","year":"2014","unstructured":"Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014;14:1\u20139.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2828_CR14","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","volume":"3","author":"H Wang","year":"2016","unstructured":"Wang H, et al. Estimates of global, regional, and National incidence, prevalence, and mortality of HIV, 1980\u20132015: the global burden of disease study 2015. Lancet HIV. 2016;3(8):e361\u201387.","journal-title":"Lancet HIV"},{"issue":"Suppl 3","key":"2828_CR15","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1097\/QAD.0000000000002321","volume":"33","author":"M Mahy","year":"2019","unstructured":"Mahy M, et al. HIV estimates through 2018: data for decision-making. AIDS. 2019;33(Suppl 3):S203.","journal-title":"AIDS"},{"issue":"7","key":"2828_CR16","doi-asserted-by":"publisher","first-page":"e0271221","DOI":"10.1371\/journal.pone.0271221","volume":"17","author":"T Gelibo","year":"2022","unstructured":"Gelibo T, et al. Spatial distribution and determinants of HIV prevalence among adults in urban ethiopia: findings from the Ethiopia Population-based HIV impact assessment survey (2017\u20132018). PLoS ONE. 2022;17(7):e0271221.","journal-title":"PLoS ONE"},{"key":"2828_CR17","doi-asserted-by":"crossref","unstructured":"Fentie Wendie T, Workneh BD. Prevalence and predictors of virological failure among adults living with HIV in South Wollo zone, Northeast ethiopia: a retrospective cohort study. HIV\/AIDS-Research and Palliative Care; 2020. pp. 393\u2013402.","DOI":"10.2147\/HIV.S266460"},{"key":"2828_CR18","unstructured":"WH O. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization Geneva; 2016."},{"key":"2828_CR19","doi-asserted-by":"crossref","unstructured":"Mayasi N et al. Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the \u2018treat-all\u2019strategy. PLoS Global Public Health. 2022;2(3):e0000259.","DOI":"10.1371\/journal.pgph.0000259"},{"key":"2828_CR20","doi-asserted-by":"crossref","unstructured":"Ghosn J et al. HIV. Lancet [Internet]. 2018 Aug [cited 2020 Sep 21];392(10148):685\u2013\u200997.","DOI":"10.1016\/S0140-6736(18)31311-4"},{"issue":"2","key":"2828_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jmv.20352","volume":"76","author":"E Nicastri","year":"2005","unstructured":"Nicastri E, et al. Clinical outcome after 4 years follow-up of HIV\u2010seropositive subjects with incomplete virologic or Immunologic response to HAART. J Med Virol. 2005;76(2):153\u201360.","journal-title":"J Med Virol"},{"issue":"suppl4","key":"2828_CR22","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1093\/cid\/cis004","volume":"54","author":"N Wadonda-Kabondo","year":"2012","unstructured":"Wadonda-Kabondo N, et al. A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. Clin Infect Dis. 2012;54(suppl4):S355\u201361.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2828_CR23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/ciu573","volume":"59","author":"K Mlisana","year":"2014","unstructured":"Mlisana K, et al. Rapid disease progression in HIV-1 subtype C\u2013infected South African women. Clin Infect Dis. 2014;59(9):1322\u201331.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2828_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/archinte.166.5.521","volume":"166","author":"FC Lampe","year":"2006","unstructured":"Lampe FC, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med. 2006;166(5):521\u20138.","journal-title":"Arch Intern Med"},{"issue":"4","key":"2828_CR25","doi-asserted-by":"publisher","first-page":"e0174767","DOI":"10.1371\/journal.pone.0174767","volume":"12","author":"F Taieb","year":"2017","unstructured":"Taieb F, et al. Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan africa: comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PLoS ONE. 2017;12(4):e0174767.","journal-title":"PLoS ONE"},{"issue":"15","key":"2828_CR26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1097\/QAD.0000000000000401","volume":"28","author":"V Jain","year":"2014","unstructured":"Jain V, et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4\u2009+\u2009T cell counts\u2009\u2265\u2009350 cells\/ul in rural Uganda. AIDS. 2014;28(15):2241.","journal-title":"AIDS"},{"issue":"2","key":"2828_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S2055-6640(20)30466-0","volume":"2","author":"S Rangarajan","year":"2016","unstructured":"Rangarajan S, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Eradication. 2016;2(2):94\u2013101.","journal-title":"J Virus Eradication"},{"issue":"5","key":"2828_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.2018.21167","volume":"321","author":"RW Eisinger","year":"2019","unstructured":"Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451\u20132.","journal-title":"JAMA"},{"key":"2828_CR29","unstructured":"Ngongo NM, et al. Human immunodeficiency virus viral load monitoring and rate of virologic suppression among patients receiving antiretroviral therapy in Democratic Republic of the congo, 2013\u20132020. Open forum infectious diseases. Oxford University Press; 2023."},{"key":"2828_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-021-00391-7","volume":"18","author":"EF Okonji","year":"2021","unstructured":"Okonji EF, et al. Determinants of viral suppression among adolescents on antiretroviral treatment in ehlanzeni district, South africa: a cross-sectional analysis. AIDS Res Therapy. 2021;18:1\u20139.","journal-title":"AIDS Res Therapy"},{"key":"2828_CR31","doi-asserted-by":"crossref","unstructured":"Negash H et al. Increased virological failure and determinants among HIV patients on highly active retroviral therapy in adigrat general hospital, Northern ethiopia, 2019: hospital-based cross-sectional study. Infect Drug Resist. 2020:1863\u201372.","DOI":"10.2147\/IDR.S251619"},{"key":"2828_CR32","doi-asserted-by":"crossref","unstructured":"Joseph Davey D, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. International journal of STD & AIDS; 2018;29(6):603\u201310.","DOI":"10.1177\/0956462417748859"},{"key":"2828_CR33","doi-asserted-by":"crossref","unstructured":"Greenbaum AH et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS (London, England), 2008;22(17):2331.","DOI":"10.1097\/QAD.0b013e32831883f9"},{"issue":"1","key":"2828_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00002030-200201040-00004","volume":"16","author":"V Le Moing","year":"2002","unstructured":"Le Moing V, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16(1):21\u20139.","journal-title":"AIDS"},{"issue":"3","key":"2828_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/QAI.0b013e31802c7e20","volume":"44","author":"RJ Bosch","year":"2007","unstructured":"Bosch RJ, et al. Pretreatment factors associated with 3-year (144-week) virologic and Immunologic responses to potent antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2007;44(3):268\u201377.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"2828_CR36","doi-asserted-by":"publisher","first-page":"e25088","DOI":"10.1002\/jia2.25088","volume":"21","author":"G Carriquiry","year":"2018","unstructured":"Carriquiry G, et al. Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean cohort. J Int AIDS Soc. 2018;21(3):e25088.","journal-title":"J Int AIDS Soc"},{"key":"2828_CR37","doi-asserted-by":"crossref","unstructured":"Agegn Gwadu A et al. Predictors of Viral Load Status Over Time Among HIV Infected Adults Under HAART in Zewditu Memorial Hospital, Ethiopia: A Retrospective Study. HIV\/AIDS-Research and Palliative Care. 2023:29\u201340.","DOI":"10.2147\/HIV.S396030"},{"issue":"5","key":"2828_CR38","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1086\/520652","volume":"45","author":"L Cuzin","year":"2007","unstructured":"Cuzin L, et al. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged\u2009>\u200950 years. Clin Infect Dis. 2007;45(5):654\u20137.","journal-title":"Clin Infect Dis"},{"key":"2828_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-020-00323-x","volume":"17","author":"E Bahemana","year":"2020","unstructured":"Bahemana E, et al. Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African cohort study. AIDS Res Therapy. 2020;17:1\u20138.","journal-title":"AIDS Res Therapy"},{"issue":"3","key":"2828_CR40","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1006\/nimg.2002.1254","volume":"17","author":"L Chang","year":"2002","unstructured":"Chang L, et al. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-na\u0131ve HIV patients. NeuroImage. 2002;17(3):1638\u201348.","journal-title":"NeuroImage"},{"key":"2828_CR41","doi-asserted-by":"crossref","unstructured":"Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sexually transmitted diseases. 2008:55\u201360.","DOI":"10.1097\/OLQ.0b013e318141fe9b"},{"key":"2828_CR42","doi-asserted-by":"crossref","unstructured":"Abdullahi IJ, Deybasso HA, Adlo AM. Determinants of virological failure among patients on first-line antiretroviral therapy in central oromia, ethiopia: a case\u2013control study. HIV\/AIDS-Research and Palliative Care. 2020:931\u20139.","DOI":"10.2147\/HIV.S281672"},{"key":"2828_CR43","doi-asserted-by":"crossref","unstructured":"Anito AA et al. Magnitude of Viral Load Suppression and Associated Factors among Clients on Antiretroviral Therapy in Public Hospitals of Hawassa City Administration, Ethiopia. HIV\/AIDS-Research and Palliative Care. 2022:529\u2013538.","DOI":"10.2147\/HIV.S387787"},{"issue":"1","key":"2828_CR44","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4102\/sajhivmed.v23i1.1356","volume":"23","author":"BA Elashi","year":"2022","unstructured":"Elashi BA, van Wyk BE. Factors associated with viral suppression among adolescents on antiretroviral therapy in free state province, South Africa. South Afr J HIV Med. 2022;23(1):1356.","journal-title":"South Afr J HIV Med"},{"issue":"20","key":"2828_CR45","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.286.20.2560","volume":"286","author":"AN Phillips","year":"2001","unstructured":"Phillips AN, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286(20):2560\u20137.","journal-title":"JAMA"},{"issue":"4","key":"2828_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00126334-200112010-00002","volume":"28","author":"G Skowron","year":"2001","unstructured":"Skowron G, Street JC, Obee EM. Baseline CD4 (+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(4):313\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"2828_CR47","doi-asserted-by":"publisher","first-page":"e0000569","DOI":"10.1371\/journal.pgph.0000569","volume":"2","author":"S Okoboi","year":"2022","unstructured":"Okoboi S, et al. Adherence monitoring methods to measure virological failure in people living with HIV on long-term antiretroviral therapy in Uganda. PLOS Global Public Health. 2022;2(12):e0000569.","journal-title":"PLOS Global Public Health"},{"issue":"10","key":"2828_CR48","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1089\/aid.2008.0141","volume":"24","author":"M Martin","year":"2008","unstructured":"Martin M, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24(10):1263\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"2828_CR49","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/QAD.0000000000000657","volume":"29","author":"MR Friedman","year":"2015","unstructured":"Friedman MR, et al. Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study. AIDS. 2015;29(9):1087\u201396.","journal-title":"AIDS"},{"issue":"4","key":"2828_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5144\/0256-4947.2015.303","volume":"35","author":"BM Musa","year":"2015","unstructured":"Musa BM, et al. Long-term outcomes of antiretroviral therapy in an adult HIV program: a 10-year retrospective cohort study in kano, Nigeria. Ann Saudi Med. 2015;35(4):303\u201311.","journal-title":"Ann Saudi Med"},{"issue":"5","key":"2828_CR51","doi-asserted-by":"publisher","first-page":"e64459","DOI":"10.1371\/journal.pone.0064459","volume":"8","author":"K Velen","year":"2013","unstructured":"Velen K, et al. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS ONE. 2013;8(5):e64459.","journal-title":"PLoS ONE"},{"issue":"5","key":"2828_CR52","doi-asserted-by":"publisher","first-page":"e97482","DOI":"10.1371\/journal.pone.0097482","volume":"9","author":"FJ Lee","year":"2014","unstructured":"Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks\u2019 follow-up. PLoS ONE. 2014;9(5):e97482.","journal-title":"PLoS ONE"},{"issue":"6","key":"2828_CR53","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/cid\/cir1034","volume":"54","author":"MW Tang","year":"2012","unstructured":"Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 world health Organization\u2013recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis. 2012;54(6):862\u201375.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2828_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hiv.12177","volume":"16","author":"KW Crawford","year":"2015","unstructured":"Crawford KW, et al. Evaluation of treatment outcomes for patients on first-line regimens in US president\u2019s emergency plan for AIDS relief (PEPFAR) clinics in U ganda: predictors of virological and immunological response from RV 288 analyses. HIV Med. 2015;16(2):95\u2013104.","journal-title":"HIV Med"},{"issue":"4","key":"2828_CR55","doi-asserted-by":"publisher","first-page":"e25030","DOI":"10.1002\/jia2.25030","volume":"20","author":"J Tanuma","year":"2017","unstructured":"Tanuma J, et al. Long-term viral suppression and immune recovery during first\u2010line antiretroviral therapy: a study of an HIV\u2010infected adult cohort in hanoi, Vietnam. J Int AIDS Soc. 2017;20(4):e25030.","journal-title":"J Int AIDS Soc"},{"key":"2828_CR56","unstructured":"Organization WH. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. World Health Organization; 2010."},{"issue":"6","key":"2828_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2217\/hiv.09.40","volume":"3","author":"BG Brenner","year":"2009","unstructured":"Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Therapy. 2009;3(6):583\u201394.","journal-title":"HIV Therapy"},{"key":"2828_CR58","doi-asserted-by":"crossref","unstructured":"Cesar C, et al. Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the caribbean: an observational cohort study. The lancet HIV. 2015;2(1):e492\u2013500.","DOI":"10.1016\/S2352-3018(15)00183-6"},{"issue":"1","key":"2828_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1677-x","volume":"16","author":"KJ Bello","year":"2016","unstructured":"Bello KJ, et al. Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect Dis. 2016;16(1):1\u20138.","journal-title":"BMC Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02828-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:34:49Z","timestamp":1759311289000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2828"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02828-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent given to the patients"}},{"value":"Human ethics and consent to participate are not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data was extracted systematically from the database we have to produce our outcome of interest. So, no human subjects were directly involved in the research which implies no need for Clinical Trial number registration.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trail number registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}